For years, the gold standard for medical knowledge has been the randomized controlled trial (RCT). While these trials are essential, they often exist in a “perfect” environment that doesn’t always mirror the messy, complex reality of daily clinical practice. That is changing. As presented at the latest EULAR Congress, the integration of real-world evidence (RWE) is shifting how we manage rheumatic and musculoskeletal diseases (RMDs), moving us toward more personalized, data-driven care.
The “Treat-to-Target” Gap: Why Implementation Matters
The “Treat-to-Target” (T2T) strategy—where clinicians aim for clinical remission or low disease activity through frequent monitoring—is the cornerstone of modern rheumatology. Yet, a recent study from Italy reveals a striking reality: in practice, we are falling short.
Analysis of nearly 1,500 outpatient visits found that T2T adherence in spondyloarthritis patients was a mere 40%. The culprit? A simple, yet devastating, documentation gap. In 90% of cases where T2T wasn’t followed, it was because clinicians weren’t recording disease activity using validated indices. When the data isn’t tracked, the strategy cannot be executed.
Weight Management and the GLP-1 Revolution
Weight management has long been a pillar of RMD care, but the emergence of GLP-1 receptor agonists (such as semaglutide and tirzepatide) has changed the conversation. Data from over 60,000 registry patients show that these medications are not just for diabetes; they are being actively used to manage weight in patients with conditions like psoriatic arthritis and ankylosing spondylitis.

The numbers are compelling: non-diabetic users saw significant weight loss, with tirzepatide often outperforming semaglutide in head-to-head patterns. As we look to the future, the focus is shifting from “just weight loss” to understanding how these drugs impact long-term joint function and disease-specific inflammation.
Early Detection of RA-ILD: A New Frontier
Rheumatoid arthritis-associated interstitial lung disease (RA-ILD) remains a major concern for clinicians due to its link to higher mortality rates. The ANCHOR-RA study, the largest prospective screening effort of its kind, recently uncovered that roughly 1 in 10 patients with RA and known risk factors already have undiagnosed ILD.
Key risk factors identified include:
- Advanced age and male sex.
- High cumulative tobacco exposure.
- Genetic markers, specifically the MUC5B promoter variant.
- Clinical signs such as crackles on auscultation and low oxygen saturation.
The Smoking Paradox in Rheumatology
While smoking rates have plummeted across the general European population, the trend in the rheumatology community is more nuanced. Recent data from the Swiss Clinical Quality Management (SCQM) registry shows that while overall smoking rates among RA patients are declining, the gap between the general population and those with RA is widening—particularly among men.
This suggests that current public health messaging isn’t reaching those most at risk of developing severe rheumatic complications. It serves as a reminder that primary prevention—quitting smoking—remains the most effective “treatment” for preventing long-term cardiopulmonary damage in RMD patients.
Frequently Asked Questions (FAQ)
What is the “Treat-to-Target” strategy?
We see a clinical approach where doctors and patients set a specific goal (usually remission or low disease activity) and adjust medications frequently until that goal is met.
Why is RA-ILD so dangerous?
Interstitial lung disease involves scarring of the lung tissue, which can reduce oxygen intake and is associated with a higher risk of mortality in patients with rheumatoid arthritis.
Can GLP-1 drugs help with joint pain?
While these drugs are primarily for weight loss and diabetes, researchers are currently investigating if the resulting weight reduction and potential anti-inflammatory effects improve overall joint health and function in RMD patients.
Are you interested in learning more about how real-world data is changing your treatment options? Subscribe to our newsletter for the latest updates in rheumatology research, or join the conversation in the comments section below.




